Sanbo Hospital Management Group (SZSE:301293) Strong Profits May Be Masking Some Underlying Issues
Sanbo Hospital Management Group (SZSE:301293) Strong Profits May Be Masking Some Underlying Issues
The market for Sanbo Hospital Management Group Limited's (SZSE:301293) stock was strong after it released a healthy earnings report last week. Despite this, our analysis suggests that there are some factors weakening the foundations of those good profit numbers.
三宝医院管理集团有限公司(深交所股票代码:301293)上周发布健康的收益报告后,其股票市场表现强劲。尽管如此,我们的分析表明,仍有一些因素削弱了这些良好利润数字的基础。
Check out our latest analysis for Sanbo Hospital Management Group
查看我们对三宝医院管理集团的最新分析
The Impact Of Unusual Items On Profit
不寻常物品对利润的影响
For anyone who wants to understand Sanbo Hospital Management Group's profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit gained from CN¥15m worth of unusual items. While we like to see profit increases, we tend to be a little more cautious when unusual items have made a big contribution. When we crunched the numbers on thousands of publicly listed companies, we found that a boost from unusual items in a given year is often not repeated the next year. Which is hardly surprising, given the name. If Sanbo Hospital Management Group doesn't see that contribution repeat, then all else being equal we'd expect its profit to drop over the current year.
对于任何想了解三宝医院管理集团在法定数字之外的利润的人来说,值得注意的是,在过去的十二个月中,从价值1,500万元人民币的不寻常物品中获得了法定利润。虽然我们希望看到利润增加,但当不寻常的物品做出重大贡献时,我们往往会更加谨慎一些。当我们计算数千家上市公司的数字时,我们发现,特定年份中不寻常的项目所带来的提振通常不会在第二年重演。考虑到这个名字,这并不奇怪。如果三宝医院管理集团认为这种贡献不会重演,那么在其他条件相同的情况下,我们预计其利润将在本年度下降。
Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Sanbo Hospital Management Group.
注意:我们始终建议投资者检查资产负债表的实力。点击此处查看我们对三宝医院管理集团的资产负债表分析。
Our Take On Sanbo Hospital Management Group's Profit Performance
我们对三宝医院管理集团盈利表现的看法
Arguably, Sanbo Hospital Management Group's statutory earnings have been distorted by unusual items boosting profit. Because of this, we think that it may be that Sanbo Hospital Management Group's statutory profits are better than its underlying earnings power. But at least holders can take some solace from the 15% per annum growth in EPS for the last three. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. In light of this, if you'd like to do more analysis on the company, it's vital to be informed of the risks involved. At Simply Wall St, we found 1 warning sign for Sanbo Hospital Management Group and we think they deserve your attention.
可以说,三宝医院管理集团的法定收益被提高利润的不寻常项目所扭曲。因此,我们认为三宝医院管理集团的法定利润可能优于其潜在盈利能力。但至少持有人可以从过去三年的每股收益每年增长15%中得到一些安慰。本文的目的是评估我们可以多大程度地依靠法定收益来反映公司的潜力,但还有很多需要考虑的地方。有鉴于此,如果你想对公司进行更多分析,了解所涉及的风险至关重要。在Simply Wall St,我们发现了三宝医院管理集团的1个警告标志,我们认为它们值得你注意。
Today we've zoomed in on a single data point to better understand the nature of Sanbo Hospital Management Group's profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.
今天,我们放大了单个数据点,以更好地了解三宝医院管理集团利润的性质。但是,如果你能够将注意力集中在细节上,总会有更多值得发现的地方。有些人认为高股本回报率是高质量业务的好兆头。尽管可能需要代表你进行一些研究,但你可能会发现这份免费收集的拥有高股本回报率的公司,或者这份内部人士正在购买的股票清单很有用。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。